Mutual of America Capital Management LLC Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Mutual of America Capital Management LLC significantly increased its holdings in Alnylam Pharmaceuticals by 673.9%, adding 11,881 shares to own a total of 13,644 shares valued at approximately $3.68 million.
• Multiple hedge funds, including Investment Management Corp of Ontario and Brevan Howard Capital Management, have also raised their stakes in Alnylam, with institutional investors now owning 92.97% of the stock.
• Analysts have positively revised their price targets for Alnylam Pharmaceuticals, with notable increases from JPMorgan Chase & Co. from $348 to $475, reflecting strong investor confidence in the stock's performance.

Mutual of America Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 673.9% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 13,644 shares of the biopharmaceutical company's stock after buying an additional 11,881 shares during the quarter. Mutual of America Capital Management LLC's holdings in Alnylam Pharmaceuticals were worth $3,684,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital World Investors grew its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Northern Trust Corp lifted its position in shares of Alnylam Pharmaceuticals by 19.6% in the 4th quarter. Northern Trust Corp now owns 878,860 shares of the biopharmaceutical company's stock worth $206,805,000 after purchasing an additional 143,941 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 60.9% in the 4th quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company's stock worth $191,391,000 after purchasing an additional 307,702 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Citigroup boosted their target price on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Jefferies Financial Group upped their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday. UBS Group increased their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Four research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $403.92.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded up $3.83 during trading hours on Friday, reaching $438.93. 901,269 shares of the stock traded hands, compared to its average volume of 1,198,893. The company has a 50 day moving average price of $331.79 and a 200 day moving average price of $284.89. The firm has a market capitalization of $57.53 billion, a price-to-earnings ratio of -177.70 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $439.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The business's quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.13) EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.